Moleculin Biotech, Inc.
Close on Oct 19, 2026
- Market cap
- $1.51M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | Before market open | – | $-3.54 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 19, 2026 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | – | $-0.49 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | – | $-0.69 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 24, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | $-2.85 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 22, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 11, 2023 | Before market open | – | – | – |
Press releases
Announcements Moleculin Biotech filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
Regulation FD disclosure · EX-99.1 to Form 8-K
Annamycin Turns “ Cold ” Pancreatic Tumors “ Hot ” in New Preclinical Data Presented at AACR
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Moleculin to Showcase New Annamycin Data at AACR Conference on
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
Results of operations · EX-99.1 to Form 8-K
Moleculin ’ s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Regulation FD disclosure · EX-99.1 to Form 8-K
CONFIDENTIAL – NOT FOR IMMEDIATE RELEASE
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
Results of operations · EX-99.1 to Form 8-K
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
Regulation FD disclosure · EX-99.1 to Form 8-K
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin ’ s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “ MIRACLE ” Phase 3 AML Trial on Pace for Q1 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin Announces New Annamycin Collaboration in Brain Tumors
Regulation FD disclosure · EX-99.1 to Form 8-K
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE
Regulation FD disclosure · EX-99.1 to Form 8-K
Moleculin Announces Grant Funded Research Evaluating Annamycin for the
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K